v3.26.1
Research and Development Revenue (Tables)
 3 Months Ended
Mar. 31, 2026
Research and Development Revenue [Abstract]  
Schedule of Revenues Disaggregated

For the three months ended March 31, 2026 and 2025, the Company’s revenues disaggregated by the major sources were as follows (in thousands):

 

   Three Months Ended
March 31,		 
   2026   2025 
BARDA  $3,311   $6,382 
Other U.S. governmental authorities   680    325 
Total revenue  $3,991   $6,707 
Schedule of Company's Contract Liabilities

The following table presents the activity in the Company’s contract liabilities during the three months ended March 31, 2026:

 

   December 31,
2025
Balance		   Additions   Reductions   March 31,
2026
Balance		 
   (in thousands) 
Contract liabilities:                
Deferred revenue  $154   $5,104   $(5,258)  $
    -
 
Total contract liabilities  $154   $5,104   $(5,258)  $
-
 

The following table presents the activity in the Company’s contract assets during the three months ended March 31, 2026:

 

   December 31,
2025
Balance		   Additions   Reductions   March 31, 2026
Balance		 
   (in thousands) 
Contract assets:                
Unbilled revenue  $849   $447   $
-
   $1,296 
Total contract assets  $849   $447   $
-
   $1,296